Simvastatin reduces sympathetic outflow and augments endothelium- independent dilation in non-hyperlipidaemic primary hypertension

Heart

Volumn 99, Issue 4, 2013, Pages 240-246

  McGowan, Cheri L ^a   Murai, Hisayoshi ^a   Millar, Philip J ^a   Notarius, Catherine F ^a   Morris, Beverley L ^a   Floras, John S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; TREATMENT OUTCOME; VASODILATATION;

ARTERIES; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN; SYMPATHETIC NERVOUS SYSTEM; VASODILATION;

EID: 84873086360     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302980     Document Type: Article

References (52)

1. Esler M, Jennings G, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3-20.
2. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics in young subjects with mild essential hypertension. J Hypertens 1993;11:647-55.
3. Floras JS, Hassan MO, Jones JV, et al. Consequences of impaired arterial baroreflexes in essential hypertension: effects on pressor responses, plasma noradrenaline and blood pressure variability. J Hypertens 1988;6:525-35.
4. Hirooka Y. Oxidative stress in the cardiovascular center has a pivotol role in the sympathetic activation in hypertension. Hypertens Res 2011;34:407-12.
5. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharm Sci 1998;19:26-37.
6. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 2008;326:278-85.
7. Kishi T, Hirooka Y, Konno S, et al. Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP. Clin Exp Hypertens 2009;31:698-704.
8. Kishi T, Hirooka Y, Mukai Y, et al. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003;21:379-86.
9. Gao L, Wang W, Li YL, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure. Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005;112:1763-70.
10. Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-8.
11. Siński M, Lewandowski J, Ciarka A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009;67:613-20.
12. Lewandowski J, Siński M, Bidiuk J, et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res 2010;33:1038-43.
13. Gomes ME, Tack CJ, Verheugt FW, et al. Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 2010;74:2622-6.
14. Siddiqi L, Joles JA, Oey PL, et al. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens 2011;29:2176-80.
15. Horwich TB, Middlekauff HR, MacLellan WR, et al. Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail 2011;17:879-86.
16. Deo SH, Fisher JP, Vianna LC, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 2012;303:377-85.
17. Hijmering ML, Stroes ES, Olijhoek J, et al. Sympathetic activation markedly reduces endothelium-dependent flow-mediated dilation. J Am Coll Cardiol 2002;39:683-8.
18. Sverrisdóttir YB, Jansson LM, Hägg U, et al. Muscle sympathetic nerve activity is related to a surrogate marker of endothelial function in healthy individuals. PLoS One 2010;5:e9257.
19. Harris KF, Matthews KA. Interactions between autonomic nervous system activity and endothelial function: a model for the development of cardiovascular disease. Psychosom Med 2004;66:153-64.
20. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170, 255 patients from 76 randomized trials. QJM 2011;104:109-24.
21. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007;25:909-20.
22. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
23. Ando S, Dajani HR, Floras JS. Frequency domain characteristics of muscle sympathetic nerve activity in heart failure and healthy humans. Am J Physiol Regul Integr Comp Physiol 1997;273:205-12.
24. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-65.
25. Butler GC, Senn BL, Floras JS. Influence of atrial natriuretic factor on spontaneous baroreflex sensitivity for heart rate in humans. Hypertension 1995;25:1167-71.
26. Pinna GD, Maestri R. New criteria for estimating baroreflex sensitivity using the transfer function method. Med Biol Eng Comput 2002;40:79-84.
27. McGowan CL, Levy AS, Millar PJ, et al. Acute vascular responses to isometric handgrip exercise and effects of training in persons medicated for hypertension. Am J Physiol Heart Circ Physiol 2006;291:1797-1802.
28. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:2-12.
29. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
30. Strazzullo P, Kerry SM, Barbatio A, et al. Do statins reduce blood pressure? A Meta-analysis of randomized, controlled trials. Hypertension 2007;49:792-8.
31. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 2005;19:21-5.
32. Schneider MP, Schmidt BM, John S, et al. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011;29:1757-64.
33. Dupuis J, Tardif JC, Rouleau JL, et al. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER Trial). Am J Cardiol 2005;96:1207-13.
34. Akalin A, Temiz G, Akcar N, et al. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008;55:861-6.
35. Morgantini C, Stea F, Boldrini B, et al. Effect of mild hyperisulinemia on conduit vessel endothelial function: role of noradrenergic activation. J Hypertens 2012;30:720-4.
36. Rattan S. 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation. Am J Physiol Gastrointest Liver Physiol 2010;298:962-9.
37. Cangemi R, Loffredo L, Carnevale R, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J 2008;29:54-62.
38. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004;35:2708-11.
39. Jamerson KA, Julius S, Gudbrandsson T, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993;21:618-23.
40. Grassi G, Dell'Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004;22:2363-9.
41. Giorda C, Appendino M, Mason MG, et al. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995;44:673-6.
42. Gomes ME, Mulder A, Bellersen L, et al. Alpha-receptor blockade improves muscle perfusion and glucose uptake in heart failure. Eur J Heart Fail 2010;12:1061-6.
43. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999;17:S29-35.
44. Derosa G, Cicero AF, D'Angelo A, et al. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clin Ther 2007;29:602-10.
45. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-6.
46. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-righ primary prevention: a meta-analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med 2010;170:1024-31.
47. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-5.
48. Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese japanese population. Am J Hypertens 1997;10:77-83.
49. Zipes DP, Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm 2006;3:108-13.
50. Barretto AC, Santos AC, Munhoz R, et al. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 2009; 135:302-7.
51. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001;103:2072-77.
52. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-31.